![FACIT in the news](http://facit-staging.gotenzing.com/wp-content/uploads/2021/11/FACIT20in20the20news20logo_0.jpg)
“U.S. biotech giant Celgene invests in Ontario-developed blood-cancer drug in potential $1-billion deal”, January 29, 2019
![](https://facit.ca/wp-content/uploads/2022/07/Portfolio.jpg)
PORTFOLIO
FACIT actively manages our diverse portfolio of Ontario oncology assets (including therapeutics, imaging, diagnostics, and technology platforms) that span all stages of commercialization, from proof-of-concept to clinical development.
![](https://facit.ca/wp-content/uploads/2022/07/Funds.jpg)
FUNDS
With critical seed funding, FACIT makes it possible for Ontario’s best cancer research discoveries to compete globally and reach patients.